Ryvu Therapeutics S.A.
RVU.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | PLN 78 | PLN 47 | PLN 39 | PLN 11 |
| % Growth | 66.4% | 20.8% | 246.9% | – |
| Cost of Goods Sold | PLN 20 | PLN 18 | PLN 17 | PLN 14 |
| Gross Profit | PLN 58 | PLN 29 | PLN 21 | -PLN 3 |
| % Margin | 74.9% | 62.5% | 55.1% | -22.7% |
| R&D Expenses | PLN 0 | PLN 0 | PLN 26 | PLN 15 |
| G&A Expenses | PLN 0 | PLN 0 | PLN 6 | PLN 4 |
| SG&A Expenses | PLN 4 | PLN 6 | PLN 6 | PLN 4 |
| Sales & Mktg Exp. | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Other Operating Expenses | PLN 176 | PLN 125 | PLN 62 | PLN 57 |
| Operating Expenses | PLN 180 | PLN 130 | PLN 93 | PLN 76 |
| Operating Income | -PLN 122 | -PLN 101 | -PLN 78 | -PLN 104 |
| % Margin | -156.6% | -215.4% | -202.1% | -927.8% |
| Other Income/Exp. Net | PLN 11 | PLN 9 | -PLN 1 | -PLN 0 |
| Pre-Tax Income | -PLN 111 | -PLN 92 | -PLN 79 | -PLN 79 |
| Tax Expense | PLN 0 | PLN 0 | PLN 5 | PLN 0 |
| Net Income | -PLN 111 | -PLN 92 | -PLN 84 | -PLN 79 |
| % Margin | -142.9% | -196.6% | -215.9% | -706.9% |
| EPS | -4.82 | -4.02 | -4.57 | -4.31 |
| % Growth | -19.9% | 12% | -6% | – |
| EPS Diluted | -4.82 | -4.02 | -4.57 | -4.31 |
| Weighted Avg Shares Out | 23 | 23 | 18 | 18 |
| Weighted Avg Shares Out Dil | 23 | 23 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 9 | PLN 14 | PLN 1 | PLN 0 |
| Interest Expense | PLN 4 | PLN 0 | PLN 1 | PLN 0 |
| Depreciation & Amortization | PLN 10 | PLN 11 | PLN 13 | PLN 13 |
| EBITDA | -PLN 97 | -PLN 81 | -PLN 65 | -PLN 66 |
| % Margin | -124.2% | -172.9% | -168% | -589.6% |